Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb;34(1):67-69.
doi: 10.1089/cap.2023.0063.

Letter to the Editor: The Impact of Adherence and CYP2C19 Phenotype on Escitalopram Exposure in Adolescents

W Thomas Baumel  1 , Ethan A Poweleit  2   3   4 , Zoe Neptune  1 , Heidi K Schroeder  1 , Laura B Ramsey  1   2   5 , Jeffrey Mills  6 , Jeffrey R Strawn  1   2   7
Affiliations

Letter to the Editor: The Impact of Adherence and CYP2C19 Phenotype on Escitalopram Exposure in Adolescents

W Thomas Baumel et al. J Child Adolesc Psychopharmacol. 2024 Feb.
No abstract available

PubMed Disclaimer

Conflict of interest statement

J.R.S. has received research support from the National Institutes of Health, the Yung Family Foundation, and PCORI. He has received material support from Myriad. He is an Associate Editor for Current Psychiatry and receives royalties from UpToDate, Springer, and Cambridge. He has provided CME lectures for the Neuroscience Education Institute, the American Academy of Child & Adolescent Psychiatry, and the American Academy of Pediatrics. He has consulted to FDA, Cerevel, Intracellular Therapeutics, and Otsuka. L.B.R. has received research support from the National Institutes of Health and has served as a consultant and received research support from BTG Specialty Pharmaceuticals. The other authors report no conflicts of interest.

Figures

FIG. 1.
FIG. 1.
Concentration time curves in four escitalopram-treated adolescents with GAD. Patient A is a CYP2C19 normal metabolizer (A), Patient B is a CYP2C19 rapid metabolizer (B), while Patients C and D are intermediate metabolizers (C, D). Escitalopram was initiated at 5 mg daily and titrated to 10 mg daily after 2 days and then 15 mg daily with the option to increase to 20 mg daily at either week 4 or 6. The dot reflects pharmacokinetic sampling. The gray dotted lines indicate the escitalopram therapeutic reference range for adults (Hiemke et al., 2018), and asterisks represent missed doses. GAD, generalized anxiety disorder.
See this image and copyright information in PMC

References

    1. Bousman CA, Stevenson JM, Ramsey LB, et al. . Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, genotypes and serotonin reuptake inhibitor antidepressants. Clin Pharmacol Ther 2023;114(1):51–68; doi: 10.1002/cpt.2903. - DOI - PMC - PubMed
    1. Hiemke C, Bergemann N, Clement HW, et al. . “Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017”: Erratum. Pharmacopsychiatry 2018;51(1–2):51; doi: 10.1055/s-0043-116492 - DOI - PubMed
    1. Jukić MM, Haslemo T, Molden E, et al. . Impact of CYP2C19 genotype on escitalopram exposure and therapeutic failure: A retrospective study based on 2,087 patients. Am J Psychiatry 2018;175(5):463–470; doi: 10.1176/appi.ajp.2017.17050550 - DOI - PubMed
    1. Strawn JR, Mills JA, Poweleit EA, et al. . adverse effects of antidepressant medications and their management in children and adolescents. Pharmacotherapy 2023;43(7):675–690; doi: 10.1002/phar.2767 - DOI - PMC - PubMed
    1. Strawn JR, Mills JA, Schroeder H, et al. . Escitalopram in adolescents with generalized anxiety disorder. J Clin Psychiatry 2020;81(5):e1–e9; doi: 10.4088/JCP.20m13396 - DOI - PMC - PubMed

Publication types

LinkOut - more resources